Stocks & Investing
Stocks and Investing
Stocks and Investing 
Wed, May 4, 2011
SANGAMO BIOSCIENCES INC (NASDAQ:SGMO), Down By 8.13% ($0.62) From $7.630 After BUYINS.NET Report Predicted Weakness After Earni
May 4, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, April 25th 2011 stating that SANGAMO BIOSCIENCES INC (NASDAQ:SGMO) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=sgmo&id=162590
At the time this story was written, SANGAMO BIOSCIENCES INC (NASDAQ:SGMO) is Down By 8.13% ($0.62) From $7.630 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
SANGAMO BIOSCIENCES INC (NASDAQ:SGMO) - Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The companys ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinsons disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC; Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; F. HoffmannLa Roche Ltd; Hoffmann-La Roche Inc.; and Open Monoclonal Technology, Inc. Sangamo BioSciences was founded in 1995 and is based in Richmond, California.
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SANGAMO BIOSCIENCES INC (NASDAQ:SGMO) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net